Generic Name and Formulations:
Diethylpropion HCl 25mg; tabs.
Various generic manufacturers
Indications for Diethylpropion:
Short-term adjunct in management of exogenous obesity.
25mg 3 times daily 1 hr before meals and in midevening for night hunger or one 75mg sustained-release tab daily in midmorning.
Arteriosclerosis. Hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug or alcohol abuse. During or within 14 days of MAOIs.
Discontinue after a few weeks as tolerance to anorectic effect occurs. Epilepsy. Cardiovascular disease. Arrhythmias. Diabetes. Prescribe limited supply to prevent overdose. Pregnancy (Cat.B). Nursing mothers.
Hypertensive crisis with MAOIs. Blocks guanethidine. Adverse reaction with alcohol. Arrhythmias may occur with general anesthetics. Antagonized by phenothiazines.
Abuse potential, impairment in hazardous activities, arrhythmias, hypertension, CNS overstimulation, psychosis, dry mouth, GI disturbances, urticaria, impotence, seizures, blood dyscrasias, dyspnea, hair loss, dysuria.
Formerly known under the brand names Tenuate, Tepanil (tabs); Tenuate Dospan, Tepanil Ten-tab (SR tabs).
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- SSRIs and SNRIs Linked to Type 2 Diabetes in Children, Adolescents
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation